Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence for Evidence Synthesis of Emerging Biologics to Improve Skeletal Health in Osteogenesis Imperfecta: Systematic Review and Meta-Analysis.

Journal of medical Internet research·2026
Same author

Prenatal Acetaminophen (Paracetamol) Use and the Risk of Autism and/or Attention-Deficit/Hyperactivity Disorder Among Sibling-Matched Cohorts.

JAMA internal medicine·2026
Same author

Methodological considerations of suicide risk following antipsychotic therapy in treatment-resistant depression.

The British journal of psychiatry : the journal of mental science·2026
Same author

Developing a Hierarchical Algorithm to Identify Pregnancies and Determine Gestational Age from Nationwide Linked Health Data in Taiwan.

Drug safety·2026
Same author

Association of Reduction in Continuity of Care During COVID-19 Pandemic With Cardiovascular Diseases, Kidney Failure and All-Cause Mortality for People With Diabetes: A Cohort Study in Hong Kong.

Diabetes, obesity & metabolism·2026
Same author

Authors' reply: Myasthenia gravis following the initiation of statin therapy.

Journal of internal medicine·2026

Related Experiment Video

Updated: Oct 3, 2025

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

2.9K

Bone-targeting agents in major solid tumour metastases: a multinational cohort study.

Ju Hwan Kim1, Chin-Yao Shen2, Philip Chun-Ming Au3

  • 1School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.

BMJ Supportive & Palliative Care
|February 18, 2022
PubMed
Summary

Bone metastasis treatment with bone-targeting agents (BTAs) like denosumab and zoledronic acid remains low across breast, prostate, and lung cancers. Understanding BTA utilization patterns is key for future patient outcome evaluations.

Keywords:
bonebreastlungprostate

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.4K
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

16.8K

Related Experiment Videos

Last Updated: Oct 3, 2025

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

2.9K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.4K
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

16.8K

Area of Science:

  • Oncology
  • Pharmacology
  • Epidemiology

Background:

  • Bone metastases are a common complication of advanced breast, prostate, and lung cancers.
  • Bone-targeting agents (BTAs) are crucial for managing skeletal-related events in these patients.
  • Understanding the real-world utilization of BTAs is essential for optimizing patient care.

Purpose of the Study:

  • To describe the epidemiology of bone metastases in breast, prostate, and lung cancer patients.
  • To characterize the clinical utilization patterns of bone-targeting agents (BTAs) in these patient populations.
  • To analyze the initiation and dynamic use of BTAs across different regions.

Main Methods:

  • Multinational retrospective cohort study.
  • Inclusion of patients with breast, prostate, and lung cancer newly initiated on BTAs (denosumab, zoledronic acid, pamidronate).
  • Data sourced from nationwide health databases in Hong Kong, Taiwan, and Korea; analysis of incidence rates and BTA initiation using Sankey diagrams.

Main Results:

  • Annual incidence of bone metastases varied by region (e.g., 3.5-4.5% in Taiwan, 9.6-10.3% in Hong Kong, 2.9-3.8% in Korea).
  • BTA initiation rates among patients with bone metastases were 14.1% (Taiwan), 9.3% (Hong Kong), and 9.4% (Korea).
  • Denosumab was most common in Taiwan and Hong Kong, while zoledronic acid dominated in Korea; dynamic switching and reinitiation patterns were observed.

Conclusions:

  • Bone-targeting agent utilization remains low across major solid tumors with bone metastases.
  • Observed dynamic utilization patterns of BTAs offer insights into the current treatment landscape.
  • Further evaluation of patient outcomes associated with BTA treatment strategies is warranted.